Retatrutide reduces liver fat dramatically
Cardiovascular outcomes (TRIUMPH-Outcomes results expected 20282029) Cancer risk (very long-term monitoring needed) Effects in special populations (elderly, multiple comorbidities) Reassurance: Phase 2 participants stopping medication in extension showed reversibility of side effects, including dysesthesia
This guide covers all of it, with the specific numbers, study references, and practical details that actually help you make an informed decision
Subject demographics (for example: age, sex, self-identified race), lab values (for example: HbA1c, BMI, liver enzymes), and some medication information (GLP-1 M, other drugs used to treat T2D, and NSAIDs) and presence or absence of diabetes-associated complications (for example: chronic kidney disease, cardiovascular disease) were extracted as prediction features
Age range The safety and efficacy of Ozempic have not been established in pediatric patients younger than 18 years of age